Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-02-14 12:50 pm Purchase | 13G | SYNDAX PHARMACEUTICALS INC SNDX | Kynam Capital Management LP | 5,660,000 6.67% | 5,660,000 (New Position) | View |
| 2024-02-14 07:01 am Sale | 13G | SYNDAX PHARMACEUTICALS INC SNDX | Point72 Asset Management L.P. | 2,834,499 3.3% | -685,903 (-19.48%) | View |
| 2024-02-13 9:44 pm Sale | 13G | SYNDAX PHARMACEUTICALS INC SNDX | Avidity Partners Management LP | 3,950,000 4.7% | -2,768,142 (-41.20%) | View |
| 2024-02-13 5:15 pm Purchase | 13G | SYNDAX PHARMACEUTICALS INC SNDX | VANGUARD GROUP INC | 4,335,353 5.11% | 4,335,353 (New Position) | View |
| 2024-02-08 10:18 am Sale | 13G | SYNDAX PHARMACEUTICALS INC SNDX | WELLINGTON MANAGEMENT GROUP LLP | 7,585,221 8.94% | -398,221 (-4.99%) | View |
| 2024-01-25 4:59 pm Purchase | 13G | SYNDAX PHARMACEUTICALS INC SNDX | BlackRock Inc. BLK | 7,015,548 8.3% | 2,663,516 (+61.20%) | View |
| 2024-01-25 11:20 am Purchase | 13G | SYNDAX PHARMACEUTICALS INC SNDX | STATE STREET CORP STT | 5,016,224 5.91% | 1,367,761 (+37.49%) | View |
| 2023-10-31 4:26 pm Purchase | 13G | SYNDAX PHARMACEUTICALS INC SNDX | Point72 Asset Management L.P. | 3,520,402 5.1% | 3,520,402 (New Position) | View |
| 2023-10-05 12:23 pm Sale | 13G | SYNDAX PHARMACEUTICALS INC SNDX | Frazier Life Sciences Public Fund L.P. | 0 0% | -3,708,838 (Position Closed) | View |
| 2023-02-14 4:46 pm Sale | 13G | SYNDAX PHARMACEUTICALS INC SNDX | Nantahala Capital Management LLC | 975,705 1.4% | -2,074,854 (-68.02%) | View |
| 2023-02-14 3:47 pm Purchase | 13G | SYNDAX PHARMACEUTICALS INC SNDX | Avidity Partners Management LP | 6,718,142 9.7% | 1,474,123 (+28.11%) | View |
| 2023-02-14 12:12 pm Purchase | 13G | SYNDAX PHARMACEUTICALS INC SNDX | Frazier Life Sciences Public Fund L.P. | 3,708,838 5.4% | 936,776 (+33.79%) | View |
| 2023-02-14 11:53 am Sale | 13G | SYNDAX PHARMACEUTICALS INC SNDX | BIOTECHNOLOGY VALUE FUND L P | 1,451,197 2.1% | -3,480,682 (-70.58%) | View |
| 2023-02-06 2:46 pm Purchase | 13G | SYNDAX PHARMACEUTICALS INC SNDX | STATE STREET CORP STT | 3,648,463 5.36% | 3,648,463 (New Position) | View |
| 2023-01-31 5:52 pm Purchase | 13G | SYNDAX PHARMACEUTICALS INC SNDX | BlackRock Inc. BLK | 4,352,032 6.4% | 662,138 (+17.94%) | View |
| 2023-01-10 09:23 am Purchase | 13G | SYNDAX PHARMACEUTICALS INC SNDX | WELLINGTON MANAGEMENT GROUP LLP | 7,983,442 11.72% | 6,384,676 (+399.35%) | View |
| 2022-03-04 5:02 pm Sale | 13D | SYNDAX PHARMACEUTICALS INC SNDX | Access Industries Holdings LLC | 2,603,709 4.7% | -78,678 (-2.93%) | View |
| 2022-02-14 1:12 pm Purchase | 13G | SYNDAX PHARMACEUTICALS INC SNDX | BIOTECHNOLOGY VALUE FUND L P | 4,931,879 8.9% | 1,221,190 (+32.91%) | View |
| 2022-02-14 08:34 am Purchase | 13G | SYNDAX PHARMACEUTICALS INC SNDX | Nantahala Capital Management LLC | 3,050,559 5.8% | 3,050,559 (New Position) | View |
| 2022-02-11 8:54 pm Purchase | 13G | SYNDAX PHARMACEUTICALS INC SNDX | Avidity Partners Management LP | 5,244,019 9.9% | 494,019 (+10.40%) | View |